Shots:
- The P-III extension studies (reSURFACE 1 & reSURFACE 2) involves assessing Ilumya (100 & 200mg) vs PBO in moderate-to-severe PsO participants with at least 50% improvement in PASI 50 at base study completion who received Ilumya within 12wks. of base study end (52 or 64wks.) were eligible to enroll in the extension study & continued on the same Ilumya dose vs PBO (q12w)
- Results: Ilumya (100 mg) @244wks., PASI 90 & PASI 100 (65.9% & 32.8%); PASI75 (88.7%). In long-term analyses, absolute PASI <1/<3/<5 scores @28wks. (50.8%, 85.1% & 96.4%, respectively) were sustained @244wks. (47.7%, 78.8% & 88.7%) respectively. Additional data results presented provide insight into the positive long-term safety profile for Ilumya in five year
- Ilumya is a humanized lgG1/k mAb, targeting the p19 subunit of IL-23 & inhibit its interaction with the IL-23 receptor and is approved in Australia, Japan & EU for PsO
Click here to read the full press release/ article | Ref: PRNewswire | Image: Business Standard
The post Sun Pharma Reports Five Year Results of Ilumya (tildrakizumab-asmn) in P-III Studies for Moderate-to-Severe Plaque Psoriasis first appeared on PharmaShots.
